+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Sevoflurane for Inhalation Market by End User (Ambulatory Surgical Centers, Clinics, Hospitals), Product (Branded, Generic), Application, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6126390
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Sevoflurane has emerged as a cornerstone of modern inhalation anesthesia, prized for its rapid onset and clearance that enable clinicians to tailor anesthetic depth with precision. Its low solubility in blood translates into swift induction and recovery times, a critical advantage in both high-volume surgical suites and ambulatory centers where turnaround is paramount. Clinicians further value its propensity for stable hemodynamic profiles and minimal airway irritability, attributes that are conducive to patient safety across diverse demographic cohorts.

Since its introduction into clinical practice, sevoflurane has evolved alongside innovations in anesthesia delivery and monitoring technologies. Regulatory bodies have underscored its safety profile through rigorous approvals, fostering confidence among practitioners and healthcare institutions. Concurrently, the anesthesiology community has refined protocols that leverage sevoflurane’s pharmacokinetic characteristics for both maintenance and induction phases, driving broader adoption across a range of surgical specialties. Transitioning from early adopters in tertiary care hospitals to wider acceptance in outpatient settings, sevoflurane now occupies a pivotal position at the intersection of clinical efficacy and operational efficiency.

Looking ahead, the prognosis for ongoing integration remains robust as healthcare providers pursue enhanced recovery after surgery protocols. Emphasizing patient-centric care models has spurred interest in sedation methods that minimize postoperative cognitive dysfunction and compress length of stay. As surgical volumes expand and acuity profiles diversify, sevoflurane’s adaptability positions it as a strategic anesthetic solution capable of meeting the demands of both high-acuity inpatient procedures and the burgeoning outpatient surgical segment.

Exploring the Pivotal Technological Advances Distribution Dynamics and Evolving Clinical Practices Driving Shifts in the Sevoflurane Market Landscape

Recent years have witnessed a series of transformative shifts that are redefining the sevoflurane inhalation landscape. Advances in anesthesia delivery systems have ushered in precision vaporizers equipped with automated controls, enabling anesthesiologists to maintain target concentrations with unparalleled consistency. In parallel, integrated monitoring platforms leverage real-time analytics and artificial intelligence algorithms to optimize dosing regimens while safeguarding patient hemodynamic stability.

Concurrently, regulatory bodies have introduced guidelines that accentuate both patient safety and environmental stewardship. Emphasis on reducing anesthetic gas emissions has catalyzed investment in closed-circuit systems and gas scavenging technologies, thereby aligning clinical operations with sustainability objectives. This trend complements growing clinician awareness of long-term occupational exposure risks and institutional commitments to green hospital initiatives.

Moreover, evolving clinical protocols such as enhanced recovery pathways and outpatient surgical programs have elevated sevoflurane’s role in facilitating rapid patient turnover and streamlined perioperative management. Its pharmacokinetic profile supports flexible anesthetic depth adjustments, which proves invaluable when tailoring care to diverse case mixes ranging from pediatric procedures to complex adult interventions. Together, these dynamics underscore a market environment characterized by continuous innovation, heightened regulatory scrutiny, and a relentless focus on optimizing both patient outcomes and operational efficacy.

Assessing the Aggregate Effects of New United States Tariff Measures on Import Costs Supply Chains and Clinical Adoption of Sevoflurane in 2025

With the introduction of new tariff measures on pharmaceutical imports in the United States during 2025, stakeholders across the sevoflurane supply chain have been compelled to reassess procurement and distribution strategies. These levies target critical inputs and finished formulations alike, prompting raw material suppliers, contract manufacturers, and end-users to evaluate the cost implications of continued reliance on cross-border supply lines.

Importers have reported incremental increases in landed costs, which in turn have influenced negotiation dynamics with manufacturers. Several anesthesia delivery system providers and hospital purchasing groups have accelerated efforts to qualify domestic contract development and manufacturing organizations as alternative sources. This drive toward nearshoring and supplier diversification has reinforced resilience but also introduced complexities related to validation timelines and regulatory inspections.

At the clinical level, anesthesia departments are recalibrating inventory management practices to mitigate exposure to sudden cost fluctuations. Multi-year supply agreements and collaborative sourcing consortia have emerged as tactical responses that distribute risk across a broader network of participants. Over the long term, the cumulative effect of these tariffs is anticipated to catalyze a structural shift toward blended supply chains that balance cost efficiency with geopolitical stability, ensuring uninterrupted access to sevoflurane in a rapidly evolving trade environment.

Furthermore, industry associations and regulatory stakeholders have engaged in policy dialogue to streamline tariff classifications and explore exemptions for essential medical gases. By fostering public-private collaboration, the sector aims to preserve both the economic viability of domestic production and the critical availability of sevoflurane for patient care.

Uncovering Strategic Segmentation Insights Across End User Product Application and Distribution Channels Shaping the Sevoflurane Market

Demand patterns for sevoflurane vary significantly across end-user segments, with ambulatory surgical centers gravitating toward agents that facilitate rapid patient turnover and minimal side effects while clinics often prioritize cost containment and ease of administration. Hospitals encompass a broad spectrum of settings-from private institutions seeking premium formulations and service partnerships to public facilities balancing tightened budgets and bulk purchasing, and teaching hospitals where training considerations influence anesthetic selection. Research institutions contribute by evaluating emerging applications and delivering evidence that informs clinical protocols, driving incremental innovation in dosage and delivery.

Product segmentation reveals a clear dichotomy between branded offerings, which emphasize proprietary delivery technologies, advanced safety features, and dedicated support services, and generic equivalents that appeal to price-sensitive customers and high-volume purchasers. While branded formats command loyalty among large health systems seeking integrated solutions, generics continue to capture attention in regions where cost efficiency supersedes differentiation.

The clinical application of sevoflurane bifurcates into induction and maintenance phases. Induction protocols leverage the agent’s rapid onset characteristics to achieve seamless transitions from conscious to anesthetized states, particularly in outpatient settings. Maintenance use capitalizes on hemodynamic stability to support prolonged procedures, with clinicians fine-tuning concentration to patient physiology and surgical complexity.

Distribution channels are equally nuanced, encompassing direct sales relationships that foster deep customer engagement, tiered distributor networks-spanning national partners capable of broad coverage and regional intermediaries with localized expertise-and an emerging e-commerce segment that streamlines procurement processes for smaller facilities and research buyers seeking on-demand access.

Analyzing Regional Market Dynamics and Growth Drivers in the Americas Europe Middle East Africa and Asia Pacific Sevoflurane Markets

In the Americas, clinical adoption of sevoflurane is underpinned by advanced anesthesia delivery infrastructure, strong regulatory alignment, and a robust network of ambulatory surgical centers. In North America, integrated health systems leverage vendor partnerships to implement state-of-the-art vaporizers and digital monitoring platforms, while Latin American markets exhibit growing demand driven by expanding surgical capacity and investments in private healthcare facilities. Regional emphasis on patient safety initiatives and enhanced recovery protocols further propels sevoflurane utilization across diverse procedural settings.

Across Europe, the Middle East, and Africa, the sevoflurane landscape reflects heterogeneous health delivery models. In Western Europe, consolidated hospital groups negotiate centralized contracts that prioritize branded formulations supported by service agreements. Regulatory harmonization within the European Union facilitates cross-border distribution, whereas Middle Eastern countries pursue infrastructure development through public-private partnerships that integrate global anesthetic standards. In Africa, constrained budgets and growing clinical training programs highlight the role of generic agents in widening access to modern inhalation anesthesia.

Within the Asia-Pacific region, a surge in surgical procedures is fueling demand for inhaled anesthetics. Government-led initiatives aimed at scaling tertiary care capacity, combined with rising medical tourism, have elevated the profile of sevoflurane in countries with advancing health systems. Training programs for anesthesiologists and collaborations between local distributors and global manufacturers accelerate technology transfer and localized service capabilities, ensuring that sevoflurane adoption keeps pace with procedural growth trajectories.

Highlighting Competitive Strategies Innovation Pipelines and Partnerships Among Leading Companies in the Sevoflurane Industry Ecosystem

Leading pharmaceutical and medical device companies have intensified efforts to differentiate their sevoflurane portfolios through innovation in formulation, delivery accessories, and end-to-end service offerings. Strategic alliances between gas monitor manufacturers and anesthesia device vendors have resulted in integrated solutions that streamline clinical workflows and enhance dosing precision. Concurrently, global suppliers have invested in capacity expansions at contract production sites to safeguard continuity of supply and accommodate surges in demand.

Merger and acquisition activity is reshaping the competitive landscape, with larger firms acquiring specialty chemical producers to internalize critical input streams and small-scale manufacturers to augment geographic reach. This consolidation trend seeks to optimize cost structures and accelerate time-to-market for enhanced vaporizers and accompanying consumables. At the same time, established players continue to cultivate collaborations with research institutions, fostering clinical studies that underpin new usage guidelines and broaden the scope of sevoflurane applications.

Emerging regional manufacturers are leveraging streamlined operations and generic production expertise to introduce cost-competitive alternatives that appeal to high-volume purchasers and public sector procurement agencies. These companies are targeting underserved zones and tailoring distribution models to local market dynamics. Looking ahead, innovation pipelines remain robust as firms explore adjunctive therapies, refined delivery mechanisms, and proprietary cartridges designed to minimize gas wastage and environmental impact.

Delivering Practical Strategic Recommendations for Industry Leaders to Navigate Challenges Capitalize on Trends and Secure Competitive Advantage

To navigate the evolving sevoflurane environment, industry leaders should prioritize diversification of their supply bases by engaging both established contract development partners and emerging domestic manufacturers. This dual approach will mitigate exposure to geopolitical disruptions while fostering competitive cost advantages. Leaders must also invest in collaborative sourcing frameworks that align procurement timing with production capacity to reduce stockout risks and enhance negotiation leverage.

Innovation remains a cornerstone of differentiation. Executives should allocate resources toward next-generation delivery systems that integrate real-time analytics and automated control features. Partnering with technology providers and clinical research teams will expedite validation of novel vaporizers and supporting consumables, driving both efficacy and safety improvements. Parallel emphasis on digital engagement platforms can deepen customer relationships and facilitate targeted educational initiatives for anesthesiology teams.

Strengthening distribution networks is equally vital. Companies should refine channel strategies by empowering national distributors to handle broad geographic coverage while granting regional partners autonomy to tailor service models to local provider needs. Simultaneously, building an e-commerce infrastructure will capture demand from smaller facilities and research entities seeking on-demand procurement options.

Finally, sustainability must be woven into strategic roadmaps. Leaders are encouraged to adopt gas capture solutions and advance eco-friendly packaging designs. By showcasing environmental stewardship alongside clinical performance, organizations can resonate with institutional priorities and regulatory expectations, securing a competitive edge in the sevoflurane domain.

Detailing Robust Research Methodology Approaches Including Primary Secondary Data Collection and Rigorous Analysis Techniques for Sevoflurane Insights

This research draws upon a blend of primary and secondary methodologies to ensure a rigorous and comprehensive analysis of the sevoflurane inhalation landscape. Primary research entailed in-depth interviews with anesthesiologists, procurement executives, and supply chain specialists, providing firsthand perspectives on clinical priorities, sourcing challenges, and innovation pathways. Structured surveys supplemented these interviews, offering quantitative insights into preferences for formulation characteristics, delivery platforms, and service models.

Secondary research encompassed an extensive review of peer-reviewed journals, regulatory filings, and government publications, which illuminated evolving guidelines and safety protocols. Industry white papers, corporate reports, and clinical trial registries were evaluated to map out the competitive terrain, delineate product pipelines, and understand the impact of recent policy shifts such as tariff implementations. This phase also integrated analysis of conference proceedings and technology showcases to capture emerging trends in anesthesia delivery.

Data triangulation was achieved by cross-referencing findings from primary dialogues with secondary sources, thereby reinforcing the validity of key conclusions. Discrepancies were resolved through follow-up consultations and iterative data validation sessions. The methodology concludes with a synthesis workshop involving subject matter experts, ensuring that the insights reflect both the latest academic research and the practical exigencies of clinical practice.

Synthesizing Key Findings Implications and Strategic Takeaways to Illuminate the Future Trajectory of the Sevoflurane Inhalation Market

The analysis underscores sevoflurane’s enduring prominence as an inhalation anesthetic, driven by its pharmacokinetic advantages, broad clinical applicability, and compatibility with evolving anesthesia delivery technologies. Transformative developments in smart vaporizers, closed-circuit systems, and sustainability initiatives are reshaping the competitive landscape, compelling stakeholders to adopt more agile sourcing and product strategies.

Segmentation insights reveal nuanced demand across end-user categories, with ambulatory surgical centers, hospital types, research institutions, branded versus generic formats, clinical applications, and distribution channels each presenting distinct opportunities and challenges. Regional dynamics further accentuate these differences, as markets in the Americas, Europe, the Middle East, Africa, and Asia-Pacific navigate unique regulatory frameworks, healthcare infrastructures, and procurement models.

Leading companies are responding through focused innovation pipelines, strategic partnerships, and targeted acquisitions, while newcomers leverage generic production capabilities to address cost-sensitive segments. In this dynamic context, actionable strategies centered on supply chain resilience, digital integration, and environmental stewardship emerge as critical differentiators. By aligning future investments with these insights, anesthetic providers and product innovators can secure a competitive position and contribute to enhanced patient outcomes across diverse procedural settings.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • End User
    • Ambulatory Surgical Centers
    • Clinics
    • Hospitals
      • Private Hospitals
      • Public Hospitals
      • Teaching Hospitals
    • Research Institutions
  • Product
    • Branded
    • Generic
  • Application
    • Induction
    • Maintenance
  • Distribution Channel
    • Direct Sales
    • Distributors
      • National Distributors
      • Regional Distributors
    • E-Commerce
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Baxter International Inc.
  • Piramal Enterprises Limited
  • Halocarbon Products Corporation
  • Viatris Inc.
  • B. Braun Melsungen AG
  • Anhui Kanglong Pharmaceutical Co., Ltd.
  • Jiangsu Nhwa Pharmaceutical Co., Ltd.
  • Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
  • Hainan Eastern Bio-Pharmaceutical Co., Ltd.
  • China National Pharmaceutical Group Co., Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing regulatory approvals for sevoflurane derivatives in emerging markets driving market expansion
5.2. Growing demand for low-solubility anesthetics boosting research investments into new sevoflurane formulations
5.3. Strategic partnerships between pharmaceutical companies and hospitals to enhance sevoflurane supply chain resilience
5.4. Integration of advanced vaporizer technologies improving precision administration of sevoflurane in operating rooms
5.5. R&D focus on minimizing environmental impact of sevoflurane through green chemistry and waste reduction initiatives
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Sevoflurane for Inhalation Market, by End User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Clinics
8.4. Hospitals
8.4.1. Private Hospitals
8.4.2. Public Hospitals
8.4.3. Teaching Hospitals
8.5. Research Institutions
9. Sevoflurane for Inhalation Market, by Product
9.1. Introduction
9.2. Branded
9.3. Generic
10. Sevoflurane for Inhalation Market, by Application
10.1. Introduction
10.2. Induction
10.3. Maintenance
11. Sevoflurane for Inhalation Market, by Distribution Channel
11.1. Introduction
11.2. Direct Sales
11.3. Distributors
11.3.1. National Distributors
11.3.2. Regional Distributors
11.4. E-Commerce
12. Americas Sevoflurane for Inhalation Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Sevoflurane for Inhalation Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Sevoflurane for Inhalation Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Baxter International Inc.
15.3.2. Piramal Enterprises Limited
15.3.3. Halocarbon Products Corporation
15.3.4. Viatris Inc.
15.3.5. B. Braun Melsungen AG
15.3.6. Anhui Kanglong Pharmaceutical Co., Ltd.
15.3.7. Jiangsu Nhwa Pharmaceutical Co., Ltd.
15.3.8. Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
15.3.9. Hainan Eastern Bio-Pharmaceutical Co., Ltd.
15.3.10. China National Pharmaceutical Group Co., Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. SEVOFLURANE FOR INHALATION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC SEVOFLURANE FOR INHALATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC SEVOFLURANE FOR INHALATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. SEVOFLURANE FOR INHALATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. SEVOFLURANE FOR INHALATION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. SEVOFLURANE FOR INHALATION MARKET: RESEARCHAI
FIGURE 24. SEVOFLURANE FOR INHALATION MARKET: RESEARCHSTATISTICS
FIGURE 25. SEVOFLURANE FOR INHALATION MARKET: RESEARCHCONTACTS
FIGURE 26. SEVOFLURANE FOR INHALATION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. SEVOFLURANE FOR INHALATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY TEACHING HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY TEACHING HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY INDUCTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY INDUCTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY MAINTENANCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL SEVOFLURANE FOR INHALATION MARKET SIZE, BY E-COMMERCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS SEVOFLURANE FOR INHALATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 81. CANADA SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. CANADA SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. CANADA SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 84. CANADA SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 85. CANADA SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 86. CANADA SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 87. CANADA SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 88. CANADA SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 89. CANADA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. CANADA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. CANADA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 92. CANADA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 93. MEXICO SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. MEXICO SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. MEXICO SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 96. MEXICO SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 97. MEXICO SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 98. MEXICO SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 99. MEXICO SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 100. MEXICO SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 101. MEXICO SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. MEXICO SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. MEXICO SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 104. MEXICO SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 105. BRAZIL SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. BRAZIL SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 117. ARGENTINA SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. ARGENTINA SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. UNITED KINGDOM SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 155. GERMANY SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. GERMANY SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. GERMANY SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 158. GERMANY SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 159. GERMANY SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 160. GERMANY SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 161. GERMANY SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 162. GERMANY SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 163. GERMANY SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. GERMANY SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. GERMANY SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 166. GERMANY SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 167. FRANCE SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. FRANCE SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. FRANCE SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 170. FRANCE SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 171. FRANCE SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 172. FRANCE SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 173. FRANCE SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 174. FRANCE SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 175. FRANCE SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. FRANCE SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. FRANCE SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 178. FRANCE SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 179. RUSSIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. RUSSIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. RUSSIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 182. RUSSIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 191. ITALY SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. ITALY SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. ITALY SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 194. ITALY SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 195. ITALY SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 196. ITALY SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 197. ITALY SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 198. ITALY SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 199. ITALY SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. ITALY SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. ITALY SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 202. ITALY SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 203. SPAIN SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. SPAIN SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. SPAIN SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 206. SPAIN SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 207. SPAIN SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 208. SPAIN SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 209. SPAIN SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 210. SPAIN SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 211. SPAIN SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. SPAIN SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. SPAIN SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 214. SPAIN SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. SAUDI ARABIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 230. SAUDI ARABIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. SOUTH AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 242. SOUTH AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 251. DENMARK SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. DENMARK SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. DENMARK SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 254. DENMARK SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 255. DENMARK SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 256. DENMARK SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 257. DENMARK SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 258. DENMARK SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 259. DENMARK SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. DENMARK SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. DENMARK SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 262. DENMARK SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 263. NETHERLANDS SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. NETHERLANDS SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. NETHERLANDS SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 266. NETHERLANDS SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. NETHERLANDS SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 274. NETHERLANDS SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 275. QATAR SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. QATAR SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. QATAR SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 278. QATAR SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 279. QATAR SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 280. QATAR SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 281. QATAR SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 282. QATAR SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 283. QATAR SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. QATAR SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. QATAR SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 286. QATAR SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 287. FINLAND SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. FINLAND SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. FINLAND SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 290. FINLAND SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 291. FINLAND SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 292. FINLAND SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 293. FINLAND SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 294. FINLAND SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 295. FINLAND SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 296. FINLAND SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 297. FINLAND SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 298. FINLAND SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 299. SWEDEN SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. SWEDEN SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. SWEDEN SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 302. SWEDEN SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 303. SWEDEN SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 304. SWEDEN SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 305. SWEDEN SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 306. SWEDEN SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 307. SWEDEN SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. SWEDEN SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 309. SWEDEN SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 310. SWEDEN SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 311. NIGERIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. NIGERIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. NIGERIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 314. NIGERIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 315. NIGERIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 316. NIGERIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 317. NIGERIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 318. NIGERIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 319. NIGERIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 320. NIGERIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 321. NIGERIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2018-2024 (USD MILLION)
TABLE 322. NIGERIA SEVOFLURANE FOR INHALATION MARKET SIZE, BY DISTRIBUTORS, 2025-2030 (USD MILLION)
TABLE 323. EGYPT SE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Sevoflurane for Inhalation market report include:
  • Baxter International Inc.
  • Piramal Enterprises Limited
  • Halocarbon Products Corporation
  • Viatris Inc.
  • B. Braun Melsungen AG
  • Anhui Kanglong Pharmaceutical Co., Ltd.
  • Jiangsu Nhwa Pharmaceutical Co., Ltd.
  • Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
  • Hainan Eastern Bio-Pharmaceutical Co., Ltd.
  • China National Pharmaceutical Group Co., Ltd.